CION Ameerpet
Fertility & Hormones · Reviewed by CION Oncologists · NABH Accredited
The Hormone IUD in Fertility-Sparing Treatment
Before anything else: standard treatment for endometrial cancer is removal of the uterus, and that is what is recommended for the overwhelming majority of women. Fertility-sparing treatment with a hormonal intrauterine system is a deliberate exception, made for a narrow group with very early, low-grade disease who want to have children, and it carries risk that must be stated rather than glossed. Within that group it works well for many, and it is a genuine option rather than a token one. This page explains how the device is used, who it suits, what the surveillance involves, and where the risk lies.
- Not standard treatment — hysterectomy is — this is an exception
- For grade 1 disease confined to the lining — criteria are strict for a reason
- Delivers progestogen straight to the lining — high local dose, limited elsewhere
- Surveillance is intensive — and it is the condition of the option
17+
Cancer Specialists
on Panel
on Panel
35+
Centres
Across India
Across India
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Who This Option Is For
The criteria are strict, and they are strict because the risk of getting this wrong is real. Every one of these must be satisfied.
| Requirement | Why it matters |
|---|---|
| Grade 1 endometrioid carcinoma | The least aggressive type and grade. Higher grades and non-endometrioid types behave in ways that make leaving the uterus in place unsafe. Given that grade involves judgement, a second pathology opinion is worth having here. See how grade is determined. |
| No invasion into the muscle wall | Confirmed on MRI. Disease confined to the lining can be treated by acting on the lining. Once it has invaded the muscle, a treatment delivered to the lining cannot reach it. This is the central requirement. See MRI. |
| No disease outside the uterus | Established by imaging. Fertility-sparing treatment addresses the uterus only, so anything beyond it makes the approach inappropriate. |
| A genuine wish to conceive | This is not a way of avoiding surgery. It is a route to having a child, accepted with its risks for that reason, and hysterectomy follows once childbearing is complete. |
| Ability to commit to surveillance | Repeated sampling of the lining at defined intervals over many months. Surveillance is the safety mechanism that makes the option defensible, and a woman who cannot attend reliably is not a candidate. |
| Understanding and accepting the risk | The honest part. Leaving a uterus containing cancer in place carries risk of progression, and a proportion of women ultimately need hysterectomy anyway. That should be stated to you plainly before you choose. See recurrence risk. |
If you do not meet all of these, being told so is good care rather than a door closing arbitrarily. The criteria exist because outside them the approach has been shown to be unsafe. Ask which criterion you do not meet and why — a specific answer is reasonable to expect, and occasionally a second opinion on grade or MRI changes it.
Did You Know? The reason a device placed inside the uterus works better here than tablets is a matter of concentration. It releases progestogen directly onto the tissue being treated, achieving a local level far higher than tablets can produce without causing systemic side effects — and it does so continuously, without depending on remembering a daily dose over many months. That combination of high local effect and reliable delivery is why regression rates are better with the intrauterine system than with oral treatment alone in comparable situations. Many units use both together for cancer, precisely because the stakes are higher than in hyperplasia. Sources: NCCN Clinical Practice Guidelines in Oncology — Uterine Neoplasms; ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma; ESHRE and ESGO guidance on fertility-sparing management.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
What Treatment Involves
A long process rather than a procedure, and the length is part of what makes it work.
- The device is inserted. A clinic procedure taking a few minutes, similar to having a coil fitted, with cramping at the time. Where the cervix is difficult it can be done under anaesthetic, sometimes at the same time as a hysteroscopy.
- Oral progestogen is frequently added. Many units use both together for cancer rather than the device alone, because the stakes are higher than in hyperplasia. Whether that applies to you is a decision for your team. See progestin treatment.
- The lining is sampled repeatedly. At defined intervals over months, usually in the clinic and usually with the device left in place. This is how response is established — not by symptoms and not by scans.
- Regression must be confirmed histologically. The whole approach rests on documented evidence that the cancer has gone from the lining. Bleeding settling proves nothing, and this is the point where the approach is most often misunderstood.
- Then conception is attempted, promptly. Usually with fertility assistance rather than waiting, because time matters and because many women in this situation have difficulty conceiving anyway. See IVF after endometrial cancer.
And afterwards, hysterectomy is recommended once childbearing is complete — because the underlying risk does not disappear and surveillance cannot continue indefinitely. See hysterectomy after childbearing.
Want Your Eligibility Assessed Properly?
Against the actual criteria, with gynae-oncology and fertility input — and an honest answer either way.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
This Is a Route to a Child
Not a way of avoiding surgery. Hysterectomy follows once your family is complete.
The Risks, Stated Plainly
Five things that should be said to you before you choose this, and sometimes are not.
The cancer may not regress
A proportion of women do not achieve regression within the agreed period, and for them hysterectomy becomes necessary. This is not treatment failure in any culpable sense — it is one of the known outcomes, and the surveillance schedule exists precisely to identify it before it becomes dangerous rather than after.
It may come back after regression
Recurrence after successful regression is well recognised, because the hormonal state that produced the cancer usually persists. It is one of the strongest arguments for conceiving promptly once regression is confirmed rather than waiting, and for completing treatment with hysterectomy afterwards. See recurrence risk.
Sampling can miss things
Surveillance biopsies sample the lining and are not a perfect test. This is a genuine limitation of the whole approach and it is the reason the criteria are strict at the outset — the safety of the strategy depends on starting from disease that is genuinely confined to the lining.
Delay carries its own cost
Months of treatment and surveillance pass before conception is attempted, and fertility declines with age. This is why fertility input belongs from the start rather than after treatment concludes, and why assisted conception is usually preferred to trying naturally.
Hysterectomy is still recommended afterwards
Once your family is complete. Some women find this harder to accept than the initial decision, because it arrives when they feel well and the crisis has passed. Knowing it is part of the plan from the beginning makes it easier than discovering it later.
Been Told Hysterectomy Is the Only Option?
If you want children, it is worth having eligibility for fertility-sparing treatment assessed properly. The opinion is free.
Practical Things Worth Knowing
Five that come up repeatedly.
- Irregular bleeding is expected at first. Spotting and unpredictable bleeding in the early months is normal with the device and is not a sign of failure. Persistent heavy bleeding is worth reporting.
- The device usually stays in for sampling. A common worry. Surveillance biopsies can normally be taken around it, so appointments do not mean removal and reinsertion each time.
- It does not affect your future fertility. The device prevents pregnancy while in place and fertility returns after removal. It does not reduce your long-term fertility, which is a frequent and unfounded concern.
- Keep your own record of appointments. Surveillance runs over many months across several departments, and this is exactly where recall lapses. Ask whose list you are on and keep a diary.
- Weight and cycles still matter. The hormonal state that produced the cancer should be addressed alongside the treatment, or it continues working against you. See PCOS.
Why This Option Needs Two Teams
Gynae-oncology decides whether it is safe. Fertility decides whether it will work. Both need to be involved from the start.
Fertility taken seriously
Slides reviewed, not just the summary line
Tumour board for every diagnosis
Scan and biopsy in one visit
Follow-up you can actually keep
Second opinions welcomed, not resented
Take The Next Step
Regression Is Proved by Biopsy
Not by bleeding settling. That distinction is the safety mechanism of the whole approach.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
The Hormone IUD in Cancer Treatment — Frequently Asked Questions
Can endometrial cancer really be treated without removing the uterus?
For a narrow group of women, yes — and it is important to be clear that this is an exception rather than the standard. Standard treatment for endometrial cancer is hysterectomy with removal of the tubes and ovaries, and that is what is recommended for the overwhelming majority. Fertility-sparing treatment applies to women with grade 1 endometrioid carcinoma that MRI shows has not invaded the muscle wall of the uterus, with no disease outside it, who wish to conceive and can commit to intensive surveillance. Within that group it works well for many. It also carries risk that should be stated to you plainly before you choose it.
Why is a device better than tablets?
Because of concentration and reliability. The intrauterine system releases progestogen directly onto the tissue being treated, achieving a local level far higher than oral tablets can produce without causing systemic side effects, and it does so continuously without depending on remembering a daily dose over many months. Regression rates are better with the intrauterine system than with oral treatment alone in comparable situations. Many units use both together when treating cancer rather than hyperplasia, precisely because the stakes are higher and the aim is to maximise the chance of regression within the available time.
How do I know whether the treatment is working?
By repeated sampling of the uterine lining at defined intervals, and by nothing else. This is the single most important thing to understand about the approach: bleeding settling does not indicate that the cancer has regressed, because progestogen controls bleeding readily whether or not the disease has responded. Regression must be confirmed histologically. Sampling can usually be done in the clinic with the device left in place. If regression has not been achieved within the agreed period, hysterectomy becomes necessary, and the surveillance schedule exists to identify that in good time.
What if the cancer comes back after it has gone?
It is a recognised outcome, because the hormonal state that produced the cancer — chronic anovulation, oestrogen from body fat — usually persists after treatment. That is the reason for two elements of the plan that can otherwise seem hurried. First, conception is attempted promptly once regression is confirmed, usually with fertility assistance rather than waiting to try naturally. Second, hysterectomy is recommended once childbearing is complete rather than continuing surveillance indefinitely. Addressing the underlying cause — weight, cycles that do not ovulate — alongside treatment also matters.
Will I definitely need a hysterectomy in the end?
It is recommended once your family is complete, and it is best understood as part of the plan from the outset rather than as something that arrives later. The reasoning is that the underlying risk does not disappear when the cancer regresses, recurrence is well recognised, and surveillance cannot reasonably continue for decades. Some women find this harder to accept than the original decision, because it comes at a point when they feel entirely well and the crisis has passed. Knowing it is coming from the beginning makes it considerably easier than encountering it as a surprise.
Medical disclaimer: This page provides general information about the hormonal intrauterine system in fertility-sparing treatment of endometrial cancer, reviewed by a CION oncologist. It is not a substitute for individual medical advice. Standard treatment for endometrial cancer is hysterectomy with removal of the tubes and ovaries; fertility-sparing treatment is appropriate only for carefully selected women and carries risks that should be discussed fully with a gynaecological oncologist before it is chosen.